anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an emulsion composition which is safe and is high in functional stability.  &lt;P&gt;SOLUTION: The emulsion composition is emulsified by means of a method of arranging a structural body in a first passage so as to guide a jet stream of fluid along the first passage and guide the fluid to controlled flow along a new passage, and determining the direction of the first passage and the new passage so as to generate shear force and cavitation in the fluid. The emulsion composition is constituted by compounding one kind or more of oily gelating agent, dipentaerythritol fatty acid ester and glycerol fatty acid ester adipic acid condensate. In addition, the emulsion composition is constituted by compounding one kind or more of glycyrrhizinic acid salt, hydroxy fatty acid, polyglycerol, polyethylene glycol, phenoxyethanol, 1,2 pentanediol, amino acid, peptide, protein, clay mineral, diethoxyethyl succinate, sphingoglycolipid, monoalkenyl glyceryl ether and monoalkenyl glyceryl ether. In addition, α-hydroxy acid is preferably compounded.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A glove lubricant composition which may be used to lubricate the surgeon&#39;s hands prior to insertion into surgical gloves comprises a homogeneous mixture of starch or lycopodium, a hydroalcoholic solution containing at least 10% of a lower (C1-6) alkanol and a dispersing agent which is preferably a carboxyvinyl polymer neutralized with polyoxyethylenecocoamine. The starch may be a modified, non-caking starch, e.g. formaldehyde or epichlorhydrin-treated starch.  Antiseptics, e.g. hexachlorophene, 2,21-thio-bis-(4,6-dichlorophenol) or 3,4,41-trichlorocarbanilide may also be included.ALSO:A glove lubricant composition which may be used to lubricate a surgeon&#39;s hand prior to insertion into surgical gloves comprises a homogeneous mixture of starch or lycopodium, a hydroalcoholic solution containing at least 10% lower (C1-6) alkanol and a dispersing agent which is preferably a carboxy vinyl polymer neutralized with polyoxyethylenecocoamine.  The starch may be a modified non-caking starch, e.g. formaldehyde- or epichlorhydrin-treated starch.  Antiseptics, e.g. hexachlorophene, 2,21-thio-bis-(4,6-dichlorophenol) or 3,4,41-trichlorocarbanilide may also be included.
This document describes systems, methods, devices, and other techniques for managing healthcare records. In some implementations, a computing system is provided that includes an electronic ledger, a first program module, and a second program module. The electronic ledger can store entries of medical record management events invoked by participants in a distributed computing network. The first program module can be assigned to an account of a first user on the distributed computing network and can identify (i) medical records of the first user and (ii) accounts of users other than the first user that are authorized to access the medical records of the first user. The second program module can be assigned to an account of a second user on the distributed computing network and can call the first program module to request access to a set of one or more of the medical records of the first user. 0) C(D -cn _0 _0 O _0 _ co0 0 &gt; 0 &gt;-0) a) W W0 0 - 0 CN 00 (D CU ( CU (DCU U) U) &#34;l (j) 0l U) J &lt; - CL J)C)-C:C,3C)
This invention relates to non-peptide somatostatin agonist compounds of formula I wherein the substituents are as defined in claim 1 and the terms alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl have the specific meanings given in the specification. Such compounds are potent with high selectivity toward the receptor subtype 2. The compounds provide an improved therapeutic index in the treatment of diabetes, cancer, acromegaly and retenosis. They are useful in the therapy of a variety of conditions which include retinal neovascularization, retinopathy, neuropathic and visceral pain, irritable bowel syndrome, ulcerative colitis, chronic atrophic gastritis, Crohn&#39;s disease, rheumatoid arthritis and sarcoidosis. They inhibit cell proliferation and cause the regression of certain tumors including breast cancer and they are useful in preventing restenosis after angioplasty and to inhibit gastric motility. Their central activities include the promotion of REM sleep and an increase in cognitive function. Many of the compounds are orally active.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition containing a kind of platelet which is produced by the contact of a platelet with a medium used in a new method of preserving platelets, erythrocytes and other akaryocytes in a powder form for a long period of time.  &lt;P&gt;SOLUTION: Platelets can be preserved for a long period of time by the contact of the platelets with the composition through a medium. The medium contains an anticoagulant, a cryoprecipitate and a coagulase. The long term preservation of platelets comprises the following steps. Step (a): To prepare a solution in which the anticoagulant, the cryoprecipitate and the coagulase are dissolved in an ordinary physiologic saline. Step (b): To obtain a solution containing platelets by adding a medium containing the platelets to the solution in step (a) and keeping it standstill. Step (c): To freeze-dry the platelet solution obtained in step (b). A kind of medium to preserve other akaryocytes is presented.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A method for a predictive prognosis of the onset of a woman&#39;s menopause is described. The method comprises the steps of accessing woman&#39;s genetic data comprising the Single Nucleotide Polymorphisms SNPs of the woman; then, processing the aforesaid woman&#39;s genetic data, to obtain a predictive prognosis of menopause onset in relation to at least one phenotype F DJ , F CK ; finally, providing as a result the aforesaid predictive prognosis of menopause onset in relation to the at least one phenotype. The aforesaid at least one phenotype F DJ , F CK  comprises at least one age group or an age limit with respect to which the predictive prognosis of menopause onset is to be carried out, or an indication of a woman&#39;s age at which the menopause onset is more likely. The aforesaid step of processing the woman&#39;s genetic data comprises, for each of the phenotypes considered F DJ , F CK , the following steps: identifying, in the woman&#39;s genetic data, a first personalized subset Sh of Single Nucleotide Polymorphisms SNPs which also belong to a first predetermined set h, associated with the phenotype considered; each of the Single Nucleotide Polymorphisms SNPs of such a first predetermined set h comprises an identifier of Single Nucleotide Polymorphisms SNPs, and is associated with a respective pre-calculated first relevance parameter β 1(Fn),i;  then, calculating a first value PRS1(F n ) of polygenic risk score, based on the first personalized subset Sh of Single Nucleotide Polymorphisms SNPs and the respective first pre-calculated relevance parameters β 1(Fn),i;  then, determining the predictive prognosis of menopause onset in relation to each of the phenotypes considered FDJ, FCK, based on the respective first value PRS1(F n ) of polygenic risk score. The method provides that the determination of the first predetermined set h of Single Nucleotide Polymorphisms SNPs and the calculation of the first relevance parameters β 1(Fn),i  are carried out in a preliminary training step, which is independent from the aforesaid step of accessing woman&#39;s genetic data and prior to the aforesaid step of processing the woman&#39;s genetic data. Such a preliminary training step comprises training at least one algorithm (A) by means of machine learning and/or artificial intelligence techniques, based on known data.
PROBLEM TO BE SOLVED: To obtain a preservative having excellent aseptic preservative efficiency, excellent in stability and safety and effectively functional over a wide range of pH by containing a polylysine and a parahydroxybenzoic acid ester. SOLUTION: This preservative is brought to contain (A) a polylysine (a lysine polypeptide produced by Actinomyces) and (B) an ester of parahydroxybenzoic acid. The mixing ratio is preferably 1 of the ingredient A to 1-30 of the ingredient B in weight ratio. The amount to be used is, e.g. in cosmetics, preferably &lt;=1 wt.% of the ingredient B. It is preferable to add (C) lauricidin (glycerol monolaurate). The preservative can be prescribed in powdery dust, wettable powder, an emulsifiable concentrate, an emulsified solution, etc.
FIELD: veterinary medicine, veterinary obstetrics. SUBSTANCE: the method deals with a cow&#39;s placenta-derived biostimulant used as a tissue preparation for subcutaneous injection. Preparation is first injected for cows at 20 ml dose 10-15 d before calving, and repeatedly for 12 h after calving. Moreover, it is conducted at the background of &#34;Tetravit&#34; prophylaxis which is injected per 10 ml twice a month for the whole dry period. EFFECT: decreased terms of placenta removal and cases of placenta delay, easier removal of delayed placenta. 1 cl, 3 tbl
PURPOSE:To obtain a DNA fragment and its derivative having excellent carcinostatic action and low side effect and useful as a carcinostatic agent. CONSTITUTION:This DNA fragment contains a sequence complementary to at least a part of sequence of a human amidophosphoribosyl transferase gene, especially contains a sequence complementary to the 2nd to 7th codons of the DNA of the above gene. The DNA derivative is e.g. a chemically modified derivative containing a unit expressed by formula [(d) is a deoxyribonucleoside unit; C is 2&#39;-deoxycytidine; T is 2&#39;-thymidine, G is 2&#39;-deoxyguanosine; p(s) is phosphorothioic acid link between 5&#39; and 3&#39; sites] in a part of the derivative. The DNA fragment is easily producible by a conventional method, e.g. using an automatic synthesizer and can be converted to the derivative by conventional method using a commercially available reagent. A pharmaceutical preparation containing the DNA fragment or the derivative as an active component can be used in the form of an injection or an oral drug.
PROBLEM TO BE SOLVED: To prepare a nail treatment agent, capable of readily removing the cuticle of a nail simply by massaging the nail without increasing the pH, smoothing the nail surface and suppressing the damage to the nail and excellent in safety by combining specific two agents. SOLUTION: This nail treatment agent is obtained by blending a scrubbing agent with an alkaline agent. The amount of the blended scrubbing agent is 0.01-20wt.%, more preferably 2-10wt.%. The scrubbing agent is a polyalkyl methacrylate, preferably polymethyl methacrylate. When an oil agent is especially enclosed in the polyalkyl methacrylate, the surface of a nail can be permeated with the oil agent in the polyalkyl methacrylate broken by the massaging to care for the damaged nail and the effects are especially highly manifested. NaOH, triethanolamine, etc., are cited as the alkaline agent and the amount thereof blended is preferably such that the pH of the nail treatment agent can be regulated to &gt;=8.5, preferably 9-11.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an orally disintegrable tablet having persistency of flavor, excellent in masking-retaining effect on medicine odor and not leaving unpleasant lingering scent feeling which is characteristic to a medicine in oral cavity/nasal cavity also after disintegrating the tablet in the oral cavity and then swallowing the tablet.  &lt;P&gt;SOLUTION: The orally disintegrable tablet is obtained by formulating a medicine with flavor particles in which an essential oil is carried on gum arabic. In the tablet, an essential oil containing an ester such as litchi oil or an essential oil containing a limonene such as lemon oil is preferably used. The unpleasant lingering scent in the oral cavity/nasal cavity can be suppressed by adding a sugar alcohol as a tablet component together with the flavor particles or adding a sweetening agent having high sweetness such as an organic acid (salt) e.g. citric acid or aspartame.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A method for remotely reviewing medical data allows medical data to be transmitted over a vulnerable network to a physician&#39;s mobile device. The method sends data to be transmitted through a console, and a data server to reach the mobile device. The method includes separating patient&#39;s medical file into a demographics layer and a data layer, separately encrypting the demographic layer and data layer using different encryption keys, and providing servers in a communication and processing system with a decryption key for the layer processed by such server. Medical file data may be separated into more than two layers. After reviewing the data, physicians may transmit their comments from their mobile device to the requestor by going through the same system. Separately encrypting different parts of a patient medical record enables processing and communication of patient medical files by intermediary servers without risking disclosure of sensitive patient information.
&lt;P&gt;PROBLEM TO BE SOLVED: To reduce generation of variation in the number of patients in a clinical test group, and to perform a series of execution of a clinical test protocol.  &lt;P&gt;SOLUTION: This clinical test protocol execution system has a server 1, a center terminal 2, and a network 11 connecting a plurality of doctor terminals 3, 4, 5, etc. such that they can transmit information to each other. The center terminal 2 performs registration processing of the protocol defining execution contents of a clinical test. The server 1 practicably stores the registered clinical test protocol, transmits information necessary for execution processing of the clinical test protocol to the doctor terminals 3, 4, 5, etc. during the processing, links each decision result to an electronic medical chart, and manages it. The doctor terminal 3, 4, 5, etc. decides a patient registration condition, randomly extracts a patient-to-test group and determines it, determines examination schedule and updates it, refers to the already registered clinical test protocol, and performs medical treatment decision by each group to perform the execution processing of the clinical test protocol.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:The titled table to disintegrate in water, etc., in a short time, blended with a zeolite retaining a gas by adsorption as a disintegrator. CONSTITUTION:A tablet blended with a zeolite retaining one or more gases selected from carbonic acid gas, oxygen, nitrogen, helium, neon, argon and hydrogen by adsorption as a disintegrator. Tablets are required to have rapidly dissolving properties, slow-dissolving properties depending upon uses. When they are added to and dissolved in a solvent such as water, etc., to prepare a solution of an active ingredient when they are used, preferably they are dissolved as rapidly as possible. When the zeolite is used as the integrator, since the tablet is disintegrated extremely in a short time and an active ingredient is released when it is added to a solvent, a solution, suspension or dispersion of the active ingredient can be rapidly prepared in use. A zeolite having 5-60wt% based on the whole composition of a synthetic zeolite shown by the formula (M is metal with valence n; x is 0.7-1.5; y is 0.8-10; z is &gt;=0) is used as the zeolite.
In a body pack, preferably a face pack for cosmetic and/or therapeutic purposes comprising a binder composition (2) and permanent magnets (3), the permanent magnets are arranged on a carrier sheet (4). The binder composition (2) is located between the permanent magnets which are magnetized at right angles relative to their surface, so that one or more poles (N, S) are present on one surface while the corresponding opposite poles (S, N) are present on the opposite surface. The carrier sheet (4) provided with the permanent magnets (3) and the binder composition (2) may be applied directly onto the body parts to be treated. It is also possible to apply the binder composition (2) first onto the body parts and to insert the carrier sheets (4) provided with the permanent magnets (3) into the binder composition thereafter. The carrier sheet (4) itself may resemble a face pack (1). &lt;IMAGE&gt;
PURPOSE:To provide the subject method for producing a porous ceramic material containing pores having a specified size and capillary passages mutually connecting the pores and communicating to the outside space, exhibiting a high affinity for a living body and useful for medical use such as regeneration of bone, electronic equipments and gene industry. CONSTITUTION:Many air bubbles having 1 to 600mum pore size are formed by frothing 100 pts.wt. egg white and the resultant air-bubbled egg white is blended with 30 to 120 pts.wt. powdery calcium phosphate compound and, as necessary, an organic fiber of &gt;=5mm length and 1 to 30mum diameter. The obtained mixture is cast into a frame mold having a desired shape and dimension and the resultant shaped mixture is heated at 120 to 150 deg.C so as to harden the egg white. Further heat treatment is then carried out at 500 to 700 deg.C so as to carbonize the egg white (and fiber) and the resultant material is subsequently heat-treated at 800 to 1350 deg.C in an oxygen-containing atmosphere so as to burn and remove the above-mentioned carbonized material and to simultaneously sinter the above- mentioned powdery calcium phosphate compound.
Despite its narrow therapeutic window, lithium is regarded as the gold standard comparator and benchmark treatment for mania. Attempts to find new drugs with similar therapeutic activities have yielded new chemical entities. However, these new drugs have yet to match the many bioactivities attributable to lithium&#39;s efficacy for the treatment of neuropsychiatric diseases. Consequently, an intense effort for re-engineering lithium therapeutics using crystal engineering is underway. The evaluation of pharmacokinetics of previously unexplored lithium salts with organic anions (i.e. lithium salicylate) has found that these lithium salts exhibit profoundly different pharmacokinetics compared to the more common FDA approved salt, lithium carbonate, in rats. Remarkably, lithium salicylate produced elevated blood and brain levels of lithium beyond 48 hours post-dose without the sharp peak that contributes to the toxicity problems of current lithium therapeutics.
1493930 Hair treatment compositions HENKEL &amp; CIE GmbH 20 Dec 1974 [21 Dec 1973] 55088/74 Heading A5B [Also in Divisions C3 and C5]  An agent for the treatment of hair comprises a water-soluble, hardenable polycondensation product being (I) a reaction product of epichlorohydrin with a polyamine containing polyoxyalkylene groups or (II) a reaction product of a compound containing more than one epoxide and/or α-halo-#-hydroxy alkyl group in the molecule with a polyamine containing polyoxyalkylene groups; and at least one additive selected from protein hydrolysates, herb extractsre-oiling agents, foam stabilisers, acids, salts, scented oils, preservative anti-dandruff agents and hair strengthening synthetic resins. A typical example of (I) is prepared to a polyglycol (M.W. 600) with epichlorohydrin to yield a polyglycol-bis-chlorohydrin ether which is then reacted with dipropylene triamine to yield a polyamine containing polyoxyalkylene groups. Reaction with further epichlorohydrin yields (I). An example of (II) is prepared by reacting epichlorohydrin with a polyglycol to yield a polyglycol-bis-chlorohydrin ether (as above) and then with epichlorohydrin to yield a polyamine containing polyoxyalkylene groups, the polyamine product being reacted with further polyglycol-bis-chlorohydrin ether to yield (II). A medicated rinse for hair comprises (I), vaseline oil, a fatty amine having a betaine structure, citric acid, herb extracts, scent and water. A hair strengthener comprises (II) a 30/70 vinyl pyrollidone/vinyl acetate copolymer, ethanol, scented oil and water. A hair conditioner comprises (I), cetylstearyl alcohol, citric acid, preservative, scent and water.
PURPOSE: A composition containing a carbon nanotube is provided to recover physical damage of brain and to suppress amyloid beta cytotoxicity. CONSTITUTION: A composition for preventing or treating brain diseases contains a carbon nanotube as an active ingredient. The brain diseases include neurodegenerative diseases or ischemic brain diseases. A composition for protecting cranial nerve contains the carbon nanotube as an active ingredient. The neurodegenerative diseases are Alzheimer&#39;s disease, Parkinson&#39;s disease, dementia, progressive supranuclear palsy, multiple system strophy, and Huntington&#39;s disease. The carbon nanotube is functionalized by carboxylic groups.
PROBLEM TO BE SOLVED: To prepare the subject composition capable of treating a state, a disease and an abnormality in eyes by directly introducing a specific microcapsule into aqueous chambers and/or vitreous bodies. SOLUTION: This composition comprises (A) a microencapsulated medicinal particle having about &lt;=300μm particle diameter. The ingredient A contains (B) a pharmacologically active medicine and (C) a pharmacologically permissible biodegradable polymer. Furthermore, the composition is degradable at a rate for providing an effective dose of the ingredient A for a long period. A pharmacologically permissible buffer agent having 10-250μm average particle diameter or at least one of a cytotoxic agent and a growth factor is preferably contained in the ingredient A. The ingredient C is preferably a condensation polymer and the composition preferably contains a liposome comprising especially an isotonic liquid, containing the ingredient A and sealed in the cavity part.
A tool to measure, diagnose and retrain post-lingually deafened cochlear implant recipients to enjoy sound and particularly musical sound. The tool includes audio and visual stimulus presentation apparatus, selected and stored musical scores, subject response apparatus, and a means to access the cochlear implant. These act in conjunction with: a Sound Enjoyment Assessment Tool (SEAT); a Perceptual Discrimination Assessment Tool (PDAT) including: a) a pitch discrimination assessment (PA) tool, and b) a timbre discrimination assessment (TA) tool. A Music Perception Ability Tool (MPAT) and a Timbre Perception Ability Retraining Tool (TPART). These components are used together initially as a composite Diagnostic Tool. The diagnostic tool produces a set of diagnostic scores of the patient&#39;s enjoyment of music. SEAT produces a musical enjoyment score. PDAT produces a pitch and timbre discrimination ability score. MPAT produces a profile of scores of the user&#39;s perceptual abilities related to music patterns and melodies.
This invention explains how to improve and/or extend human life by optimizing metabolic processes. This patent teaches how to reestablish or correct pathways that have been altered either by biochemical stress or by genetic mutation. The body&#39;s energetic mitochondrial machinery is programmed for optimization at birth. As events are encountered throughout its lifecycle the cells respond to these stresses by altering their metabolic configurations to meet the immediate demands. Each of these successive adaptive biochemical reactions cumulatively magnifies previous compensatory switches from the original optimal metabolic pathways and diminishes the individual&#39;s quality of life and lifespan. As we age these opportunistic adjustments continue to compound and further reduce metabolic efficiency to levels that significantly compromise health and longevity. Modern technology, including molecular biology and micro or nano electronics, is applied to assess the multiple impaired metabolic pathways in an individual and to employ biologic interventions and tools that eliminate those diversions and/or correct genetic and/or epigenetic mutations.